Kyverna Therapeutics (KYTX) files $300M mixed shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/5/2026
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
- LCI Industries names interim CEO as Jason Lippert retires
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
Form S-3 Kyverna Therapeutics,
March 26, 2026 4:22 PM EDTAs filed with the Securities and Exchange Commission on March 26, 2026
... More